StockLearn from Clustermicro · Stock Breakout ScannerStockLearn

Amanta Healthcare Limited (AMANTA)

Hospitals & Diagnostics · NSE · end-of-day 2026-10-19

₹164.63

Day change

-10.24%

1-year

+23.8%

From 52-week high

-20.5%

Weinstein stage

Stage 2

Minervini template

7/8

Amanta Healthcare Limited closed at ₹164.63 on 2026-10-19, up 24% over the past year, 20% below its 52-week high. It meets 7 of 8 conditions of Minervini's trend template; Weinstein's stage analysis reads stage 2 - advancing; on earnings, it passes 0 of 3 SEPA checks. Over the year its annualised volatility was about 43%, with a largest fall of 29% from a peak.

Price, RSI and MACD

6M1Y

Price · +21.9% over the period

RSI (14) · 36.0

MACD (12, 26, 9) · histogram -2.59

Price · +22.8% over the period

RSI (14) · 36.0

MACD (12, 26, 9) · histogram -2.59

Price: daily close adjusted for splits and bonuses, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

Fundamentals

Market cap	Sales (TTM)	Net profit (TTM)	P/E	EPS (TTM)	P/B	ROE	Debt / equity	Free cash flow	Beta
—	₹291 cr	₹15 cr	39.6	4.16	2.57	—	1.06	₹-32 cr	0.73

Quarterly results

Quarter	Sales ₹ cr	Net profit ₹ cr	EPS	EPS YoY	Sales YoY	Net margin
Jun 2026	69	3	0.85	-30.3%	+5.3%	4.8%
Mar 2026	77	6	1.61	—	—	7.2%
Dec 2025	74	5	1.35	—	—	6.2%
Sep 2025	71	1	0.35	—	—	1.7%
Jun 2025	65	4	1.22	—	—	5.4%

Standalone · EPS restated onto today's share count after splits and bonuses · net profit as filed.

Minervini SEPA — earnings checks 0 of 3 pass

Check	Result
Latest quarter EPS up 25%+ on a year ago	✗ Fail
EPS growth accelerating over 3 quarters	— Not assessable
Sales up 25%+, or sales growth accelerating	✗ Fail
Annual EPS up 25%+ in each of the last 2 years	— Not assessable
Net margin above the same quarter last year	✗ Fail

Investor methods

Method	Checks	Score	Verdict
Minervini	✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✗ Close above the 50-day ✓ At least 25% above the 52-week low · low 95.03 ✓ Within 25% of the 52-week high · high 207.08 ✓ RS percentile 70 or more · RS 76 Trend template - the gate, measured: a modest 21-day edge.	7/8	7 of 8
Weinstein	Stan Weinstein's stage analysis on the 30-week moving average.		Stage 2 - advancing
CAN SLIM	✗ C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✗ N within 15% of the 52-week high · high 207.08 ✓ S more volume on up days than down days (50 sessions) · 2.45x ✗ L RS percentile 80 or more · RS 76 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist.	2/5	Weak
Darvas	✗ New 52-week high in the last 120 sessions Darvas needs a new 52-week high to start a box.	10/100	No box
Turtle	✗ Close above the prior 55-session high · 209.95 ✗ Close above the prior 20-session high · 207.56 ✓ Close below the prior 20-session low · 173.11 Donchian channel breakout - the Turtle traders' entry.		Breakdown
Graham	✗ Price at or below the Graham number · Graham number 77.43 ✗ P/E 15 or less · P/E 39.6 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 2.57 ✗ Current ratio 2 or more · 1.69 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests.	47/100	Expensive

Each method's own rules applied to this stock - information, not a buy or sell signal. All were tested on 2024-26 data; only the Minervini trend template showed a consistent edge.

Hospitals & Diagnostics sector — top 10 by 1-year return

Stock	1M %	3M %	6M %	1Y %	3Y %	5Y %	P/E	P/B	ROE %	ROCE %	ROA %	D/E	EV/EBITDA	₹ Cr	Sales TTM ₹ Cr	Profit TTM ₹ Cr	EPS	Beta
AMANTA this stock	-13.3	-0.0	+21.9	+34.8	—	—	39.6	2.57	—	—	—	1.06	—	—	291	15	4.2	0.73
SAKAR	-21.8	+2.7	+51.5	+162.7	+158.4	+464.3	57.0	6.33	10.0	12.9	—	0.17	30.8	2,054	272	36	16.2	0.69
KOVAI	-5.6	-0.9	+7.0	+128.0	+118.8	+256.0	25.5	4.87	19.4	—	—	—	—	6,429	—	—	234.2	—
AHCL	+17.8	+79.8	+86.2	+112.4	—	—	11.1	6.23	47.4	—	—	0.19	30.7	1,434	—	—	2.4	0.44
VIJAYA	-12.2	+2.5	+33.7	+37.9	+134.0	+143.8	75.1	14.71	19.7	30.3	—	0.00	39.6	14,078	857	188	18.2	0.54
ENTERO	-13.2	+26.4	+18.2	+35.9	—	—	52.2	3.88	6.7	10.7	—	0.34	26.4	6,545	7,128	168	28.8	0.36
YATHARTH	-14.8	+14.4	+30.6	+19.8	+147.7	—	51.6	5.18	10.0	12.4	—	0.14	30.2	9,356	1,334	174	18.8	0.88
LALPATHLAB	-2.8	+8.9	+30.0	+18.6	+47.0	-0.3	56.8	12.32	21.6	29.1	—	0.00	36.2	30,900	2,891	546	32.5	0.41
THYROCARE	-15.3	-15.2	+19.9	+13.6	+151.4	+22.7	42.6	12.80	28.8	37.8	—	0.00	28.2	7,497	876	176	11.1	0.47
STARHEALTH	-0.9	-6.7	+7.0	+7.6	-8.9	—	35.7	3.15	8.9	—	—	—	—	31,904	—	—	15.3	0.41
METROPOLIS	-13.1	-9.5	+9.2	+7.1	+37.5	-24.5	53.4	7.11	13.4	19.6	—	0.01	26.3	10,763	1,710	203	9.7	0.43

A blank in a return column means the stock is younger than that window. P/B and ROE come from each company's own filings where held.

Hospitals & Diagnostics stocks of a similar size

Asterdm Growwhospi North Eastern Carrying Corporation Limited Lotus Eye Hospital And Institute Limited Gaudium Ivf And Women Health Limited Mastertr Bajaj Healthcare Limited Gpt Healthcare Limited

The live scanner - every stock ranked, filtered by method, stage and sector, with interactive charts - is in the StockLearn app. Open the StockLearn scanner →

Prices as of 2026-10-19, end of day, from NSE. Fundamentals from each company's own exchange filings (XBRL), EPS restated for splits and bonuses. Figures may be delayed and are for information only.

For research & education only — not investment advice. The methods, checks and verdicts are automated rules applied to public data, not buy/sell recommendations. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by the NSE or any exchange. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.

Terms · Privacy · Disclaimer · Refund · Contact